Recent 8-K filings for RDGL

• February 10, 2025, 6:59 PM ET other material materiality 0.60 neutral item 3.02item 8.01

  Vivos raises $1.5M via 12.5M share sale; also issues warrants for 6.25M shares at $0.15

  Issued 12.5M common shares to an accredited investor for gross proceeds of $1.5M under Regulation A+ offering.

• February 10, 2025, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Vivos reports positive initial RadioGel clinical trial results; plans expansion to 50 patients

  First 5 patients showed safety; Y-90 remained at injection site with no adverse events.

• July 1, 2024, 7:59 PM ET regulatory materiality 0.60 neutral item 8.01item 9.01

  Vivos files IDE amendment with FDA to initiate human trials of Radiogel therapy

  Filed IDE amendment with FDA for Radiogel™ Precision Radionuclide Therapy, addressing 63 prior FDA comments.

• July 11, 2022, 7:59 PM ET other materiality 0.60 neutral item 3.02item 8.01item 9.01

  Vivos raises $1.2M from 15M share sale and $20K from warrant issuance

  Gross proceeds of $1.2M from 15M shares of common stock sold under Regulation A+ on July 7, 2022.

Materiality & sentiment trend

Max materiality 0.65 · Median 0.50 · Most common event other_material

2 positive 0 negative 12 neutral

source · RDGL on sec.gov